Department of Pulmonary and Critical Care Medicine, Ajou University School of Medicine, Suwon, South Korea.
Department of Internal Medicine, Kangwon National University, Chuncheon, South Korea.
Int J Chron Obstruct Pulmon Dis. 2023 May 2;18:733-743. doi: 10.2147/COPD.S388367. eCollection 2023.
A comprehensive analysis of the effects of inhaled corticosteroids (ICS) on COPD in a real-world setting is required due to safety concerns regarding ICS in COPD. This study aimed to explore the impact of ICS on the prognosis of Asian COPD patients in the real-life world.
We examined 978 COPD patients registered in the Korean National Health and Nutrition Examination Survey (KNHANES) database and with their data linked to Health Insurance and Review Assessment (HIRA) data. The outcome measures were ascertained by HIRA from January 1, 2009, to December 31, 2012. This study enrolled two arms; ICS users (N = 85, mean age = 66.7 ± 8.9 years) and non-ICS users (N = 893, mean age = 63.7 ± 9.7 years).
Compared to the non-ICS users, the ICS users had a higher rate of pneumonia, tuberculosis, and acute exacerbations (<0.05). Hospitalization due to respiratory causes was also higher among ICS users (<0.05). Multivariate analysis showed that acute exacerbation was independently associated with the development of pneumonia (<0.05), whereas ICS therapy had a tendency to be associated with pneumonia. Another multivariate analysis demonstrated that old age, FEV, ICS therapy, and pneumonia were independently associated with the occurrence of acute exacerbation (<0.05). The concomitant pneumonia (HR = 3.353, = 0.004) was independently associated with higher mortality (<0.05).
Our data demonstrated that the ICS users had a higher rate of pneumonia and tuberculosis and the concomitant pneumonia was independently associated with higher mortality, highlighting the importance of cautious and targeted administration of ICS in COPD.
由于吸入性皮质类固醇(ICS)在 COPD 中的安全性问题,需要对其在真实环境中对 COPD 的影响进行全面分析。本研究旨在探讨 ICS 对亚洲 COPD 患者真实世界预后的影响。
我们检查了韩国国家健康和营养检查调查(KNHANES)数据库中登记的 978 名 COPD 患者及其与健康保险和审查评估(HIRA)数据相关的数据。结果测量由 HIRA 从 2009 年 1 月 1 日至 2012 年 12 月 31 日确定。本研究包括两个臂;ICS 用户(N=85,平均年龄=66.7±8.9 岁)和非 ICS 用户(N=893,平均年龄=63.7±9.7 岁)。
与非 ICS 用户相比,ICS 用户肺炎、结核病和急性加重的发生率更高(<0.05)。ICS 用户因呼吸原因住院的情况也更高(<0.05)。多变量分析显示,急性加重与肺炎的发生独立相关(<0.05),而 ICS 治疗有与肺炎相关的趋势。另一项多变量分析表明,年龄较大、FEV、ICS 治疗和肺炎与急性加重的发生独立相关(<0.05)。同时患有肺炎(HR=3.353,=0.004)与死亡率升高独立相关(<0.05)。
我们的数据表明,ICS 用户肺炎和结核病的发生率较高,同时患有肺炎与死亡率升高独立相关,这强调了在 COPD 中谨慎和有针对性地使用 ICS 的重要性。